- Email: [email protected]
Pall speeds processing for drug discovery
NEWS Editorial Office: Elsevier Advanced Technology, P O Box 150, Kidlington Oxford OX5 1AS, UK Tel: +44 (0)1865 843676 Fax: +44 (0)1865 843971 E-mail: [email protected]
Editor: Helen Long
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Pall speeds processing for drug discovery Pall Corp has introduced a new sample preparation tool that enables laboratories to process hundreds of samples simultaneously. The AcroPrep 384 multi-well filter plate optimizes the identification of novel leads and targets for drug development – technology that is used in countless DNA and protein sample preparation and detection processes. Using patented technology, the AcroPrep 384 multi-well filter plate eliminates lateral cross contamination, or ‘crosstalk’, that can slow down the screening process. Crosstalk occurs when the signal from one well inadvertently enters adjacent wells. The new Pall plate eliminates this problem by individually sealing each well so signals cannot travel from one to the other, enabling laboratories to process 384 samples in minutes. Pall says it developed its new line of multi-well filter plates in response to the move to higher-throughput, lower-volume formats necessary to speed the rate of drug discovery. The multi-well filter plates are available in 96 and 384 well formats, and are offered with multiple membrane options and well volumes to meet various application needs. Contact: Pall Corp, Life Sciences Groups, 600 South Wagner Road, Ann Arbor, MI 48103-9019, USA. Tel: +1 734 665 0651, Fax: +1 734 913 6114.
Once the evaluation has been completed to the specified requirements of Serologicals, the companies say that they will discuss a more extensive commercial agreement for the purification and commercialization of other plasma proteins. “The Gradiflow technology offers an attractive alternative to the existing technologies of fractionation and chromatography with potentially higher yields at similar or superior quality,” said David Dodd, president and chief executive officer of Serologicals Corp.” “Mass-producing medically relevant products was the intention for the Gradiflow system, and we have the highest confidence that this agreement with Serologicals will clearly demonstrate this,” said Gradipore’s chief executive officer Robert Lieb. Serologicals, which is based in Atlanta, Georgia, provides biological products and enabling technologies that are needed for the research, development and manufacture of biologically based life science products. Contacts: Gradipore Inc (USA), 4 Skyline Drive, Hawthorne NY 10532 USA, PO Box 553, Elmsford NY 10523, USA. Tel: +1 914 592 1060, Fax: +1 914 592 3899. Gradipore Ltd, 22 Rodborough Road, Frenchs Forest, NSW 2086, Australia. Tel: +61 2 8977 9000, Fax: +61 2 8977 9099. Serologicals Corp, 5655 Spalding Drive, Norcross, GA 30092, USA. Tel: +1 678 728 2000, Fax: +1 678 728 2299.
Consolidated acquires further Gradipore and Serologicals work water operations Consolidated Water Co Ltd of together Grand Cayman, British West US companies Gradipore and Serologicals Corp have announced a development agreement for evaluating the use of Gradipore’s membrane-based Gradiflow separations technology for isolating plasma proteins intended for use as diagnostic reagents, culture medium supplements, or for therapeutic indications.
Indies, Cayman Islands, has completed multiple acquisitions that have expanded its water operations into the British Virgin Islands and Barbados, and also increased its presence at home and in the Bahamas. The company, which develops and operates reverse osmosis seawater conversion facilities, says that
after meeting numerous conditions, including the receipt of certain governmental approvals, the acquisitions were completed for an aggregate purchase price of around US$25.5 million. This is subject to adjustment based on audited yearend financial statements of the acquired companies. Separately, Consolidated has contracted to sell its non-voting stock in the British Virgin Islands company to a local group for US$2.1 million. It now has responsibility for the operation of additional water plants with a combined production capacity of approximately 30 million litres (8.0 million gallons) per day, bringing its current total production capacity to about 40 million litres (10.9 million gallons) per day. “As a result of these acquisitions, Consolidated is now producing and/or delivering desalinated water to customers in five Caribbean countries,” observed Jeffrey Parker, the company’s chairman and chief executive officer. “We also acquired the exclusive rights to distribute a line of highly efficient energy recovery systems to desalination plant operators throughout the Caribbean basin.” Contact: Consolidated Water Co Ltd, Trafalgar Place, West Bay Road, Grand Cayman, British West Indies, Cayman Islands. Tel: +1 345 945 4277, Fax: +1 345 949 2957.
GEA extends plant testing capabilities US-based GEA Filtration has introduced an extension to its standard Model R membrane filtration pilot-plant product line. The new Model R-xp is engineered and built to NEC Class 1, Division I, Group C & D hazardous area construction standards. This allows membrane filtration applications to be tested that employ non-water-based solvent systems which have potentially explosive characteristics. The company says that this is especially important to maintain safe testing for a small-scale commercial production environment
Membrane Technology April 2003
Editor: Helen Long
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Pall speeds processing for drug discovery Pall Corp has introduced a new sample preparation tool that enables laboratories to process hundreds of samples simultaneously. The AcroPrep 384 multi-well filter plate optimizes the identification of novel leads and targets for drug development – technology that is used in countless DNA and protein sample preparation and detection processes. Using patented technology, the AcroPrep 384 multi-well filter plate eliminates lateral cross contamination, or ‘crosstalk’, that can slow down the screening process. Crosstalk occurs when the signal from one well inadvertently enters adjacent wells. The new Pall plate eliminates this problem by individually sealing each well so signals cannot travel from one to the other, enabling laboratories to process 384 samples in minutes. Pall says it developed its new line of multi-well filter plates in response to the move to higher-throughput, lower-volume formats necessary to speed the rate of drug discovery. The multi-well filter plates are available in 96 and 384 well formats, and are offered with multiple membrane options and well volumes to meet various application needs. Contact: Pall Corp, Life Sciences Groups, 600 South Wagner Road, Ann Arbor, MI 48103-9019, USA. Tel: +1 734 665 0651, Fax: +1 734 913 6114.
Once the evaluation has been completed to the specified requirements of Serologicals, the companies say that they will discuss a more extensive commercial agreement for the purification and commercialization of other plasma proteins. “The Gradiflow technology offers an attractive alternative to the existing technologies of fractionation and chromatography with potentially higher yields at similar or superior quality,” said David Dodd, president and chief executive officer of Serologicals Corp.” “Mass-producing medically relevant products was the intention for the Gradiflow system, and we have the highest confidence that this agreement with Serologicals will clearly demonstrate this,” said Gradipore’s chief executive officer Robert Lieb. Serologicals, which is based in Atlanta, Georgia, provides biological products and enabling technologies that are needed for the research, development and manufacture of biologically based life science products. Contacts: Gradipore Inc (USA), 4 Skyline Drive, Hawthorne NY 10532 USA, PO Box 553, Elmsford NY 10523, USA. Tel: +1 914 592 1060, Fax: +1 914 592 3899. Gradipore Ltd, 22 Rodborough Road, Frenchs Forest, NSW 2086, Australia. Tel: +61 2 8977 9000, Fax: +61 2 8977 9099. Serologicals Corp, 5655 Spalding Drive, Norcross, GA 30092, USA. Tel: +1 678 728 2000, Fax: +1 678 728 2299.
Consolidated acquires further Gradipore and Serologicals work water operations Consolidated Water Co Ltd of together Grand Cayman, British West US companies Gradipore and Serologicals Corp have announced a development agreement for evaluating the use of Gradipore’s membrane-based Gradiflow separations technology for isolating plasma proteins intended for use as diagnostic reagents, culture medium supplements, or for therapeutic indications.
Indies, Cayman Islands, has completed multiple acquisitions that have expanded its water operations into the British Virgin Islands and Barbados, and also increased its presence at home and in the Bahamas. The company, which develops and operates reverse osmosis seawater conversion facilities, says that
after meeting numerous conditions, including the receipt of certain governmental approvals, the acquisitions were completed for an aggregate purchase price of around US$25.5 million. This is subject to adjustment based on audited yearend financial statements of the acquired companies. Separately, Consolidated has contracted to sell its non-voting stock in the British Virgin Islands company to a local group for US$2.1 million. It now has responsibility for the operation of additional water plants with a combined production capacity of approximately 30 million litres (8.0 million gallons) per day, bringing its current total production capacity to about 40 million litres (10.9 million gallons) per day. “As a result of these acquisitions, Consolidated is now producing and/or delivering desalinated water to customers in five Caribbean countries,” observed Jeffrey Parker, the company’s chairman and chief executive officer. “We also acquired the exclusive rights to distribute a line of highly efficient energy recovery systems to desalination plant operators throughout the Caribbean basin.” Contact: Consolidated Water Co Ltd, Trafalgar Place, West Bay Road, Grand Cayman, British West Indies, Cayman Islands. Tel: +1 345 945 4277, Fax: +1 345 949 2957.
GEA extends plant testing capabilities US-based GEA Filtration has introduced an extension to its standard Model R membrane filtration pilot-plant product line. The new Model R-xp is engineered and built to NEC Class 1, Division I, Group C & D hazardous area construction standards. This allows membrane filtration applications to be tested that employ non-water-based solvent systems which have potentially explosive characteristics. The company says that this is especially important to maintain safe testing for a small-scale commercial production environment
Membrane Technology April 2003